Guggenheim Elevates Abivax as Its Leading Biotech Pick Ahead of Key Data Readout
Guggenheim has identified Abivax as its top idea in the biotechnology sector ahead of a pivotal Phase III data readout scheduled for the end of June. The firm emphasized management’s detailed disclosure plan covering topline safety, combined exposure-adjusted incidence rates from Phase II/III, and maintenance efficacy. While Guggenheim sees the set…